| For: | Brar AS, Khanna T, Sohal A, Hatwal J, Sharma V, Singh C, Batta A, Chandra P, Mohan B. Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review. World J Cardiol 2026; 18(1): 111954 [PMID: 41607621 DOI: 10.4330/wjc.v18.i1.111954] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v18/i1/111954.htm |
| Number | Citing Articles |
| 1 |
Elizaveta A. Rogozhkina, Anna A. Ivanova, Olga N. Dzhioeva, Anton R. Kiselev, Oksana M. Drapkina. Ultrasound-derived congestion phenotypes and their association with cardiac structure and function in HFpEF. Exploration of Medicine 2026; 7 doi: 10.37349/emed.2026.1001410
|
| 2 |
Souradipta Ganguly, Betul Gunes, Yusu Gu, Jorge Suarez, Gautam Gupta, Kei Ishizuka, Rabi Murad, Tatiana Kisseleva, Wolfgang Dillmann, Kirk Peterson, Eric Adler, David A. Brenner, Debanjan Dhar. A translational model of MASLD-associated HFpEF defines mitochondrial dysfunction and cardiac plasticity during disease progression and regression. Metabolism 2026; 182 doi: 10.1016/j.metabol.2026.156682
|
| 3 |
Ruri Okubo, Nobutomo Yamamoto, Xiaojun Shao, Taku Omori, Jian Xiong, Changhui Liu, Ryo Kato, Masahiko Murata, Tetsuji Kitano, Yuki Ito, Tomoka Oka, Toshiaki Onitsuka, Eishi Motomura, Kaoru Dohi, Gang Zhu, Motohiro Okada. Risk of Long-Term Clozapine Medication over Decades for Cardiac Adverse Events Including Heart Failure and Its Pathophysiology: A Japan and China Retrospective Cohort Analysis. Medical Sciences 2026; 14(2) doi: 10.3390/medsci14020306
|
| 4 |
Junli Wu, Wenwen Zheng, Qianxian Qi, Chaojie He, Changlin Zhai, Hongyan Fan. Metabolic Dysfunction–Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives. Reviews in Cardiovascular Medicine 2026; 27(6) doi: 10.31083/RCM51234
|
| 5 |
Pooja Khatiwala, Joseph Ragan, Ashley Michael, Kyle Gleaves. Glycogenic Hepatopathy Mimicking Overlapping with Metabolic Dysfunction-Associated Steatotic Liver Disease in Newly Diagnosed Type 2 Diabetes: A Case Report. Sage Open Medical Case Reports 2026; 14 doi: 10.1177/2050313X261492855
|
| 6 |
Yanqiu Huang, Yadan Xu, Chenghao Zhang, Wen Gu, Yue Li, Haojia Zhang, Tian Wang, Tangyi Su, Yangchen Lhamu, Yichen Chen, Liang Zhou, Lipeng Hao, Yang Yang, Hui Wang. Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study. Cardiovascular Diabetology 2026; 25(1) doi: 10.1186/s12933-026-03208-x
|
| 7 |
Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen. Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics. BMJ Open Gastroenterology 2026; 13(1) doi: 10.1136/bmjgast-2026-002343
|
| 8 |
Zubaier Ahmed, Nashrah Mustafa, Tamanna Sarkar, Hasina Yasmin. Beyond Weight Loss: Tirzepatide as a Metabolic Disease‐Modifying Strategy for Metabolic Dysfunction‐Associated Steatohepatitis: A Narrative Review. Health Science Reports 2026; 9(8) doi: 10.1002/hsr2.73044
|
| 9 |
Jing Zhou, Nenghan Zhang, Jiajun Li, Xiangqi Qin, Lingqi Kong, Liang Bai, Tuo Han. Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review. Exploration of Endocrine and Metabolic Diseases 2026; 3 doi: 10.37349/eemd.2026.101481
|
| 10 |
Tessa Straatmijer, Midas Mulder. New therapeutic options for metabolic‐associated steatotic liver disease. British Journal of Clinical Pharmacology 2026; doi: 10.1002/bcp.70795
|
| 11 |
Mario Romeo, Fiammetta Di Nardo, Claudio Basile, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Alessia De Gregorio, Marcello Dallio, Alessandro Federico. From FIB-4 to the Artificial Intelligence Era: The Evolution of Non-Invasive Tools (NITs) for Tailored Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Livers 2026; 6(4) doi: 10.3390/livers6040071
|
| 12 |
Akash Batta, Arka De, Omesh Goyal, Aalam Sohal. Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions. Frontiers in Epidemiology 2026; 6 doi: 10.3389/fepid.2026.1893613
|
| 13 |
Mohamed Yousef Abdallah Y. Omar, Amany Mansour E. El-mallah, Mohamed Gamal M.A. Bakr, Mohamed Mahmoud E. Ragab. Cardiovascular disease risk in patients with and without metabolic dysfunction-associated steatotic liver disease: A clinical and subclinical evaluation. American Heart Journal Plus: Cardiology Research and Practice 2026; 70 doi: 10.1016/j.ahjo.2026.100865
|
| 14 |
Muneera AlTaweel, Mareyah Alshaikh Husain, Maram Rashid AlSubaiee, Ali Al Qarni, Ibraheem Aldossary. BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia. Current Medical Research and Opinion 2026; 42(5) doi: 10.1080/03007995.2026.2692167
|
| 15 |
Nebyu Yonas Shanka, Chavdar S. Pavlov, Taisiia A. Turankova, Temesgen Tesfaye Ajabo, Leul Mekonnen Nigatu, Biniyam Esayas Dana, Poorani Gurumallesh Prabu. Predicting Clinically Significant Portal Hypertension in MASLD Using Routine Ultrasound and Clinical Data: A Retrospective Cohort Study. BioMed Research International 2026; 2026(1) doi: 10.1155/bmri/1662756
|
| 16 |
Mengyao Yan, Qian Xiang. Metabolic Syndrome: From Mechanisms to Therapeutic Interventions. MedComm 2026; 7(9) doi: 10.1002/mco2.70934
|
| 17 |
Nakul Mahajan, Nazdeep Kaur, Samar Pal S Sandhu, Vyoma Patel, Hunardeep Kaur Boparai, Kanwarmandeep Singh, FNU Rajinderpal Singh. Fibrosis-Driven Cardiovascular Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease: Emerging Links With Atherosclerotic Cardiovascular Disease. Cureus 2026; doi: 10.7759/cureus.115501
|
| 18 |
Ileana Pantea, Angela Repanovici, Hamza Islam. Tirzepatide in Metabolically Dysfunctional‐Associated Steatohepatitis (MASH): A Bibliometric and Evidence‐Based Review. Journal of Diabetes Research 2026; 2026(1) doi: 10.1155/jdr/1853763
|